United States Patent 5,571,817: Scope, Claims, Expiration, and Finasteride Patent Landscape

U.S. Patent No. 5,571,817 protected the oral use of finasteride, chemically identified as 17β-(N-tert-butylcarbamoyl)-4-aza-5α-androst-1-en-3-one, for treating androgenic alopecia. Its claims covered treatment of androgenic alopecia generally and male pattern alopecia specifically. The patent issued on November 5, 1996, expired on June 19, 2013, and received a six-month pediatric extension through December 19, 2013. It no longer blocks generic finasteride marketing in the United States. [1][2][3]

What drug and indication did U.S. Patent 5,571,817 protect?

The patented active ingredient is finasteride, the 5α-reductase inhibitor marketed by Merck as Propecia for male pattern hair loss and as Proscar for benign prostatic hyperplasia.

The patent addressed androgenic alopecia, also called androgenetic alopecia or male pattern hair loss. It did not claim finasteride as a chemical compound. Earlier Merck patents covered the compound and related 5α-reductase inhibitors.

Patent attribute	U.S. Patent 5,571,817
Patent title	Treatment of androgenic alopecia
Active ingredient	Finasteride
Chemical name in claim	17β-(N-tert-butylcarbamoyl)-4-aza-5α-androst-1-en-3-one
Therapeutic area	Androgenic alopecia
Administration route	Oral
Patient population	Humans
Patent type	Method-of-treatment patent
Issue date	November 5, 1996
Original term endpoint	June 19, 2013
Pediatric extension	Through December 19, 2013
Patent status	Expired

The patent’s commercial significance came from its relationship to Propecia, which the FDA approved in December 1997 for the treatment of male pattern hair loss in men. [3][4]

What do the claims of U.S. Patent 5,571,817 cover?

What is the scope of claim 1?

Claim 1 requires the following elements:

A method of treating androgenic alopecia.
The patient must be a human.
The patient must be in need of treatment.
Finasteride must be administered orally.
The administered amount must be therapeutically effective.

Claim 1 is therefore a use claim, not a product claim. It does not claim every finasteride tablet, every finasteride formulation, or every use of finasteride.

A claim chart is set out below.

Claim limitation	Scope
“A method”	Requires performance of a treatment method
“Treating androgenic alopecia”	Requires the claimed therapeutic purpose
“Human in need”	Excludes nonhuman use and patients without the claimed condition
“Orally administering”	Requires oral delivery
“Therapeutically effective amount”	Requires an amount effective for the claimed treatment
Named compound	Requires finasteride, not merely any 5α-reductase inhibitor

The claim does not recite a specific tablet strength, dosing interval, duration of treatment, excipient, coating, particle size, release profile, or manufacturing process.

What does claim 2 add?

Claim 2 depends on claim 1 and limits the disease to male pattern alopecia. It therefore requires every limitation of claim 1 plus treatment of male pattern alopecia.

Claim 2 does not create an independent formulation or composition right. It is narrower than claim 1 because it limits the form of androgenic alopecia covered.

What does U.S. Patent 5,571,817 not cover?

The patent does not expressly cover:

Finasteride as a chemical compound.
Finasteride tablets as compositions of matter.
Topical finasteride.
Nonhuman treatment.
Benign prostatic hyperplasia.
Female pattern hair loss as a separately defined indication.
A particular dosage, such as 1 mg.
A particular tablet formulation.
A manufacturing process.
A method of reducing dihydrotestosterone without treating androgenic alopecia.

A product manufacturer could still face other patent or regulatory issues if a separate patent covered a formulation, dosage regimen, manufacturing process, or use. Those risks were separate from the expired claims of the '817 patent.

When did U.S. Patent 5,571,817 expire?

The patent’s ordinary term ended on June 19, 2013. The FDA granted pediatric exclusivity that extended the relevant protection period by six months, through December 19, 2013. [2][3]

Finasteride exclusivity timeline

Event	Date
Earliest relevant patent priority	June 19, 1992
Patent issued	November 5, 1996
FDA approval of Propecia	December 19, 1997
Original patent expiration	June 19, 2013
Pediatric extension endpoint	December 19, 2013
Post-expiration generic market	Open after December 19, 2013, subject to FDA approval

The patent was filed under the pre-Uruguay Round patent-term regime. Its term was therefore generally measured as 17 years from issuance, subject to applicable adjustments and extensions, rather than 20 years from the earliest nonprovisional filing date.

What was the Orange Book status of finasteride?

The FDA listed Propecia patents in the Orange Book, including U.S. Patent Nos. 5,571,817 and 5,670,643. The listings were associated with the approved finasteride 1 mg product and its male pattern hair loss indication. [2]

The Orange Book listing gave Merck a basis to sue ANDA applicants that made Paragraph IV certifications challenging the listed patents. It did not extend the patent beyond its statutory term.

The relevant regulatory distinctions were:

The '817 patent was a method-of-use patent.
A generic applicant could address the patent through a Paragraph IV certification or a section viii statement, depending on the proposed labeling and the listed use.
The patent’s expiration and pediatric extension ultimately removed the principal U.S. patent barrier to generic finasteride 1 mg for male pattern hair loss.
Orange Book listing did not create a separate patent right against unapproved or off-label use.

Which related patents covered finasteride and Propecia?

The '817 patent sat within a broader Merck finasteride portfolio.

Patent	General subject matter	Commercial relevance
U.S. Patent No. 4,760,071	4-aza steroidal 5α-reductase inhibitors, including finasteride-related chemistry	Earlier compound and pharmaceutical protection
U.S. Patent No. 5,571,817	Oral finasteride treatment of androgenic alopecia	Core Propecia method-of-use patent
U.S. Patent No. 5,670,643	Related androgenic alopecia treatment claims	Companion Propecia patent listing
Other Merck patent families	Benign prostatic hyperplasia, dosage, formulation, and related 5α-reductase inhibitor uses	More relevant to Proscar and broader finasteride development

The earlier composition patent was more important to initial finasteride exclusivity than the '817 patent, but it expired before the Propecia indication patent. By the time generic manufacturers entered the hair-loss market, the relevant commercial barrier was primarily the method-of-use patent estate and its pediatric extension.

What formulation patents protected Propecia?

U.S. Patent 5,571,817 does not claim a formulation. It does not require:

A specific amount of finasteride per tablet.
A particular excipient system.
A film coating.
A dissolution profile.
A tablet hardness or size.
A specific manufacturing sequence.

The patent therefore offered limited protection against alternative finasteride formulations. A competitor using a different excipient system would still be within the patent if it orally administered finasteride to treat androgenic alopecia during the patent term. Conversely, a generic manufacturer did not need to copy the Propecia formulation to enter after expiration.

Formulation freedom was commercially important because generic finasteride tablets could use different inactive ingredients while maintaining the same active ingredient, strength, dosage form, and bioequivalence profile required by the FDA.

Did U.S. Patent 5,571,817 cover topical finasteride?

No. The claim expressly requires oral administration. A topical finasteride product would not literally satisfy the oral-administration limitation.

During the patent term, a topical product could still have raised separate questions involving:

Induced infringement based on labeling or promotional materials.
Equivalents arguments.
Other patents covering topical delivery.
FDA approval requirements.
Combination or formulation patents.

After December 19, 2013, the expired '817 patent could not block topical finasteride on its own.

How strong was the patent estate for Propecia?

The estate was strong during its effective term but narrow in claim architecture.

Strengths

It directly covered the approved oral treatment of androgenic alopecia.
It matched Propecia’s principal commercial indication.
It required the same active ingredient and route used by the branded product.
It was listed in the Orange Book.
The pediatric extension delayed fully unencumbered generic entry by six months.

Limitations

It was a method claim rather than a composition claim.
It did not cover the molecule itself.
It did not claim a specific dose.
It did not claim a tablet formulation.
It did not cover topical administration.
Direct infringement required performance of the treatment method.
Enforcement against generic manufacturers depended heavily on the proposed labeling, marketing conduct, and inducement theories.

Once the patent expired, its residual defensive value was zero against ordinary U.S. generic entry. The patent remains relevant for historical validity, infringement, settlement, and prosecution analysis, but not as a current exclusionary right.

Were there Paragraph IV challenges to Propecia patents?

Generic manufacturers challenged the listed Propecia patents through the ANDA process. Paragraph IV certifications assert that a listed patent is invalid, unenforceable, or not infringed.

Under the Hatch-Waxman framework, Merck could file patent litigation after receiving a Paragraph IV notice. A timely suit generally triggered a 30-month stay of FDA approval, subject to statutory exceptions and court developments. [5]

The relevant litigation issues included:

Whether the asserted claims were valid.
Whether the generic applicant’s proposed labeling induced infringement.
Whether the patent claims were properly listed for the approved indication.
Whether the ANDA applicant could rely on a section viii carve-out.
Whether a settlement delayed or permitted generic launch.

The expiration of the '817 and related Propecia patents ultimately made these disputes commercially temporary. Generic finasteride products entered the U.S. market after the patent and pediatric exclusivity periods ended.

What patent litigation affected finasteride generic entry?

Merck faced ANDA litigation involving generic applicants seeking to market finasteride products. The disputes centered on the Propecia patent listings, including U.S. Patent Nos. 5,571,817 and 5,670,643.

The practical litigation risk was greater for a generic seeking a label that expressly included male pattern hair loss. A generic using a section viii carve-out for a patented indication could reduce infringement exposure, but the strategy depended on the precise Orange Book listing, proposed labeling, and marketing conduct.

The main litigation outcomes relevant to market entry were:

Issue	Commercial effect
Paragraph IV notice	Allowed the brand to sue before approval
30-month stay	Could delay FDA approval
Patent invalidity finding	Could accelerate entry
Noninfringement finding	Could permit launch before expiration
Settlement	Could establish a negotiated entry date
Expiration	Removed the patent-based injunction risk

No current injunction can arise from the expired '817 patent.

Did licensing deals affect the '817 patent?

The commercially important rights were held and enforced by Merck, the developer and sponsor of Propecia. Publicly documented commercialization of Propecia did not depend on a separate third-party license that remains relevant after expiration of the patent.

Historical licenses, supply arrangements, or settlement agreements could affect particular parties, but they do not revive an expired patent. A settlement could have governed launch timing or litigation conduct, but its commercial relevance would depend on the parties and contractual terms.

What generic entry risks existed after patent expiration?

After December 19, 2013, the principal barrier to generic finasteride 1 mg for male pattern hair loss was regulatory approval rather than the '817 patent.

Remaining risks included:

FDA refusal to approve an ANDA.
Failure to demonstrate bioequivalence.
Labeling disputes.
Separate unexpired patents, if any, covering a particular formulation or method.
Product-liability exposure.
State-law substitution and pharmacy-channel issues.
Commercial competition from multiple generic manufacturers.

The patent did not prevent a generic from using a different tablet design or excipient system. The generic needed to satisfy FDA requirements for the proposed dosage form and labeling.

Was there biosimilar risk for Propecia?

No. Finasteride is a small-molecule drug, not a biologic. Propecia competitors entered through the generic drug framework, principally under section 505(j) of the Federal Food, Drug, and Cosmetic Act, rather than through the biosimilar pathway under the Public Health Service Act.

The relevant competitive terms were generic, ANDA, bioequivalence, Paragraph IV, and section viii. “Biosimilar” is not the correct regulatory classification for finasteride.

How did the U.S. patent estate compare with geographic protection?

U.S. Patent 5,571,817 provided protection only in the United States. It could not block:

Manufacture wholly outside the United States, unless another U.S. patent applied to importation or related conduct.
Sales in foreign markets.
Foreign regulatory approvals.
Foreign use of finasteride.

Foreign counterparts were governed by local patent laws, patent-term rules, examination outcomes, supplementary protection certificates, and national litigation. The U.S. expiration date did not establish the expiration date in Europe, Canada, Japan, or other markets.

What manufacturing and intellectual-property barriers remained?

The '817 patent imposed no manufacturing-process limitation. A manufacturer did not need to reproduce Merck’s manufacturing process to make finasteride after patent expiration.

Potential barriers could instead arise from:

Process patents.
Polymorph or crystallization patents.
Formulation patents.
Manufacturing know-how.
FDA chemistry, manufacturing, and controls requirements.
Supplier qualification.
Controlled quality specifications.
Trademark restrictions involving Propecia branding.

Finasteride itself is a well-characterized small molecule. After loss of compound and method-of-use exclusivity, the competitive barrier shifted from patent exclusion to regulatory execution, cost, supply reliability, and market access.

Key Takeaways

U.S. Patent 5,571,817 covered oral administration of finasteride to treat androgenic alopecia.
Claim 2 narrowed the indication to male pattern alopecia.
The patent did not claim finasteride itself, a tablet formulation, a specific dose, or topical use.
The patent issued on November 5, 1996.
Its ordinary expiration date was June 19, 2013.
Pediatric exclusivity extended protection through December 19, 2013.
Propecia’s principal U.S. regulatory and patent barrier has expired.
Finasteride is a small molecule, so generic competition proceeded through ANDAs, not biosimilar applications.
The patent’s commercial importance was historical. It no longer blocks U.S. generic finasteride entry.

Frequently Asked Questions

Can a generic manufacturer sell finasteride for male pattern hair loss today?

Yes, subject to FDA approval and compliance with applicable labeling and regulatory requirements. The '817 patent and its pediatric extension have expired.

Did the '817 patent cover finasteride for benign prostatic hyperplasia?

No. The asserted claims are directed to androgenic alopecia. Finasteride’s BPH use was associated with the Proscar product and separate patent and regulatory history.

Could the '817 patent block a topical finasteride product?

Not literally, because the claims require oral administration. Other patents or infringement theories could have mattered during the patent term, but the '817 patent itself is expired.

Was claim 1 limited to a 1 mg dose?

No. Claim 1 does not recite a numerical dose. It requires a therapeutically effective amount of finasteride administered orally.

Does expiration of the '817 patent eliminate all finasteride intellectual-property risk?

No. It eliminates the exclusionary effect of this patent. Separate formulation, process, polymorph, labeling, trademark, regulatory, or contractual rights could present different risks.

References

United States Patent and Trademark Office. (1996). U.S. Patent No. 5,571,817: Treatment of androgenic alopecia. U.S. Department of Commerce.
U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.
U.S. Food and Drug Administration. (1997). Propecia (finasteride) prescribing information. Merck & Co., Inc.
U.S. Food and Drug Administration. (1997). FDA approves Propecia for male pattern hair loss. FDA.
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0155096	⤷ Start Trial	SPC/GB93/006	United Kingdom	⤷ Start Trial
European Patent Office	0155096	⤷ Start Trial	93C0055	Belgium	⤷ Start Trial
Austria	46912	⤷ Start Trial
Austria	67503	⤷ Start Trial
Austria	78827	⤷ Start Trial
Australia	2748192	⤷ Start Trial
Australia	3313589	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,571,817

Summary for Patent: 5,571,817